These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3293069)

  • 1. BCG in carcinoma in situ and superficial bladder tumors.
    Lamm DL
    Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
    [No Abstract]   [Full Text] [Related]  

  • 2. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
    [No Abstract]   [Full Text] [Related]  

  • 3. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of superficial carcinoma of the bladder.
    Paulson DF
    Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
    Bouffioux C
    Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428
    [No Abstract]   [Full Text] [Related]  

  • 8. Superficial bladder disease: case studies and therapeutic advances.
    Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
    Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
    [No Abstract]   [Full Text] [Related]  

  • 9. BCG vaccine in urinary bladder cancer.
    Brosman SA
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
    [No Abstract]   [Full Text] [Related]  

  • 10. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BCG immunotherapy in the treatment of superficial bladder tumors].
    Samodai L; Drinóczy M; Kolozsy Z; Mohácsi L; Dauda G; Porkoláb Z
    Orv Hetil; 1986 Oct; 127(40):2441-6. PubMed ID: 3537907
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 14. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 15. BCG therapy of superficial bladder tumors.
    Herr HW
    Prog Clin Biol Res; 1989; 303():369-74. PubMed ID: 2674999
    [No Abstract]   [Full Text] [Related]  

  • 16. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
    Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
    Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment modalities in superficial bladder cancer.
    Irwin R; Zincke H; Droller MJ; Prout GR; Soloway MS
    Semin Urol; 1989 Feb; 7(1 Suppl 1):1-12. PubMed ID: 2499916
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
    Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
    Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
    [No Abstract]   [Full Text] [Related]  

  • 20. Innovative approaches for superficial bladder tumors.
    Oosterlinck W; Abi-Aad A
    Acta Urol Belg; 1996 May; 64(2):31-2. PubMed ID: 8701806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.